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Abstract 
Background: There is increasing interest in using extracellular vesicle‑derived microRNAs (miRNAs) as biomarkers 
in renal dysfunction and injury. Preliminary evidence indicates that miRNAs regulate the progression of glomerular 
disease. Indeed, exosomes from the renal system have provided novel evidence in the clinical setting of albuminuria. 
Thus, the aim of this study was to quantify the urinary miRNAs present in exosome and microvesicles (MVs), and to 
assess their association with the presence of increased urinary albumin excretion in essential hypertension.
Methods: Exosomes were collected from urine specimens from a cohort of hypertensive patients with (n = 24) or 
without albuminuria (n = 28), and from 20 healthy volunteers as a control group. Urinary exosomes were phenotyped 
by Western blot, tunable resistive pulse sensing, and electronic microscopy. Expression of miR‑146a and miR‑335* was 
analysed by qRT‑PCR and any associations between albuminuria and exosomal miRNAs were analysed.
Results: Urinary miRNAs are highly enriched in exosome subpopulations compared to MVs, both in patients with or 
without increased albuminuria (p < 0.001), but not in the control group. High albuminuria was associated with 2.5‑fold 
less miR‑146a in exosomes (p = 0.017), whereas miR‑146a levels in MV did not change. In addition, exosome miR‑146a 
levels were inversely associated with albuminuria (r = 0.65, p < 0.0001), and discriminated the presence of urinary 
albumin excretion presence [area under the curve = 0.80, 95% confidence interval: 0.66–0.95; p = 0.0013].
Conclusions: Our results indicate that miRNAs were enriched in the urinary exosome subpopulation in hyperten‑
sive patients and that low miR‑146a expression in exosomes was associated with the presence of albuminuria. Thus, 
urinary exosome miR‑146a may be a potentially useful tool for studying early renal injury in hypertension.
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Background
Increased urinary albumin excretion (UAE) is a marker 
for cardiovascular and renal disease [1–3]. Its prognos-
tic value in hypertensive patients without diabetes and 
in subgroups of the general population has been well 
established over the past few years [4–6]. In presence 
or absence of diabetes, elevated blood pressure is one 
the main factors related to increased UAE. Moreover, 
the management of hypertension reduces the levels and 
the progressive rate of rise of UAE [7]. Even though an 
association between blood pressure and UAE has been 
established, the mechanisms mediating albuminuria 
progression in hypertensive patients are less well-under-
stood. Thus, in recent years, interest in the potential 
role of epigenetics in the origin and progression of renal 
lesions in hypertension has increased.
microRNAs (miRNAs) are small (18–22 nucleotides), 
non-coding RNA molecules which are post-transcrip-
tional regulators of gene expression [8]. The expression 
of these molecules is often tissue-restricted, and this 
fact has led to the idea that miRNA expression may have 
organ-specific roles [9, 10], and that these miRNAs are 
also delivered to different extracellular biofluids [11]. 
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vesicles from endocytic compartments, that have been 
shown to play a novel role in cell communication and 
the interchange of intercellular genetic material [12]. 
Microvesicles are distinctive from exosomes in that they 
are produced by shedding of the plasma membrane and 
usually larger in size (150 nm–1 µm). Besides lipids, and 
proteins, exosomes also contain various nucleic acid spe-
cies including functional miRNAs and small RNA, but 
little mRNA [13]. However, it has been suggested that 
microvesicles hold functional messenger RNA (mRNA) 
and little miRNA [14].
It is believed that urinary exosomes may be derived 
from the kidney and urinary tract, and that these are pas-
sively filtered through the glomerulus and/or secreted by 
the renal tubules [12, 15]. Therefore, the urinary exosome 
cargos could be generated by the glomerular (podocytes, 
mesangial and endothelial cells) and tubular cells to exert 
their functions throughout of the nephron. Therefore, 
exosomes may constitute paracrine effectors in the cross-
talk, between different cell types in the kidney [16].
Preliminary evidence indicates that miRNAs may regu-
late the progression of glomerular and tubular disease. 
Therefore, selective sorting of miRNAs into exosomes 
from the renal system may provide novel evidence in the 
clinical setting of albuminuria [12, 17, 18]. Our group 
previously showed that urinary exosome miRNAs are 
enriched in patients with systemic lupus erythemato-
sus and that lupus nephritis (proteinuria) increases the 
quantity of urinary exosomal miRNAs, especially miR-
146a [19]. The miR-146a is a key regulator of immune 
responses negatively modulating the interferon-γ pathway 
[20], has been also involved in renal inflammation [9] and 
fibrosis regulating extracellular matrix protein production 
in diabetes [21]. In addition, previous works reported that 
miR-146a was augmented in lupus nephritis [19, 22] and 
that is highly expressed in podocytes [23, 24]. While, miR-
335* is an abundant miRNA in urine to test the specificity 
of miR-146a association results with UAE [11].
However, whether extracellular vesicle (EV) miRNA 
expression is different between exosomes and microvesi-
cles, whether EV miRNA levels are increased or can 
serve as biomarker for early renal injury in hypertension 
remains largely unknown. In the present study, we inves-
tigated the selective sorting of miRNA into exosomes 
(high levels than in microvesicles) and the potential role 




Urinary samples were collected from patients with essen-
tial hypertension who were recruited at the Internal Med-
icine Department in the Hospital Clínico Universitario in 
Valencia (Spain). Hypertension was defined according 
the European Society of Hypertension criteria: systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pres-
sure ≥ 90  mmHg) [7]. Of these patients 24 had albumi-
nuria (UAE normalized by urinary creatinine > 30 mg/g) 
and 28 were normoalbuminuric. All patients received 
antihypertensive treatment at the time the study was car-
ried out, and average time to disease progression was 
almost 5  years. Twenty healthy volunteers were ana-
lysed as a control group with normal renal function, nor-
mal urinalysis, and no history of urinary tract infection, 
renal stones, or other renal or genitourinary disease (age 
35.3 ± 7.0, 70% female). The study protocol was approved 
by the Ethics Committee of the Hospital Clínico Univer-
sitario of Valencia in accordance with the Declaration 
of Helsinki of 1975 as revised in 2008. All subjects have 
signed a written informed consent.
Measurement of urinary albumin excretion
Urinary albumin excretion was measured in morning 
urine collections using a nephelometric immunoassay 
(Behring Institute). The level of albuminuria for each 
patient was considered as the mean value obtained from 
the morning spot urine samples and expressed as the 
albumin (mg) to creatinine (mg) ratio (ACR). Increased 
UAE was defined as an ACR ≥ 30 μg/mg. In our labora-
tory, the intra-assay, inter-assay, and intra-individual 
coefficients of reproducibility for UAE measurement 
were 2%, 6%, and 12%, respectively.
Exosome isolation
The two EV subpopulations—exosomes and MVs—were 
isolated from the urine specimens using a combination 
of centrifugation, ultracentrifugation, and treatment with 
DTT, as previously described [19]. A 50 mL exosome and 
MV pellets were resuspended in 100  μL of sterile PBS 
for protein quantification, electron microscopy and tun-
able resistive pulse sensing (TRPS), and the other 50 mL-
pellet was resuspended in 100 μL of sterile PBS for RNA 
isolation. The exosomes and MVs were then immediately 
processed, as described below, to extract their RNA.
Tunable resistive pulse sensing (TRPS)
A qNano Gold instrument (Izon Science Ltd., Christch-
urch, New Zealand) was used for TRPS. Both the EV 
preparations and the calibration particles (supplied by 
Izon) were diluted 1:100 in PBS. The exosomes were 
measured using NP150 nanopores and CPC200 calibra-
tion beads (mode 203 nm) while the MVs were quantified 
using NP400 and CPC400 beads (mode 335 nm); 40 µL 
of each EV sample type were loaded into the instrument 
and at least 500 events were measured for each sample. 
Data was recorded using the Izon Control Suite Software 
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v.2.2.2.111. The default minimum blockade height 
(0.05  nA) for particle detection was used and pressure 
was set to 1.2 kPa.
Transmission electron microscopy
Approximately 30 μL of each sample type (exosomes or 
MVs) was resuspended in PBS and placed on parafilm. A 
formvar carbon-coated nickel grid was then positioned 
on top of each drop for 15 min in dry environment before 
the samples were stained with 2% uranyl acetate for 
5 min in the dark. Excess liquid was wicked off the grid, 
and grids were stored at room temperature until imaging 
was performed using a CM-10 Phillips transmission elec-
tron microscope.
Western blot analysis
Total exosome and MV protein was prepared by resus-
pending each sample type in RIPA lysis buffer (50  mM 
Tris–HCl pH 7.4, 150  mM NaCl, 0.5% sodium deoxy-
cholate, 1% NP-40, and 0.1% sodium dodecyl sulfate) 
containing 2  μg/mL leupeptin and 20  ng/mL aprotinin, 
on ice for 20 min. Total protein quantity was calculated 
by the Lowry method. Approximately 20 μg of total pro-
tein from each sample were electrophoresed on 4–12% 
Bis–Tris NUPAGE SDS-PAGE (Life Technologies, USA) 
under non-reducing conditions and was then trans-
ferred to a polyvinylidene fluoride (PVDF) membrane. 
These were subsequently blotted with primary anti-
bodies against CD9 (Santa Cruz Biotechnology, USA), 
TSG101 (Abcam, UK), calnexin, GM-130, and nucleo-
porin 62 (Abcam, UK), and β-actin (Sigma, St Louis, 
USA) followed by a secondary IgG alkaline phosphatase 
peroxidase antibody (Sigma, St Louis, MO, USA). The 
immunoreactive bands were visualised using nitro blue 
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate 
(NBT/BCIP, Sigma, USA) substrate system and quanti-
fied using TotalLab TL-100 (v.2008) software.
RNA extraction
Total RNA was extracted from exosome and microvesi-
cle pellets using a total exosome RNA and protein isola-
tion kit (Invitrogen, Life Technologies, USA) from 100 μL 
of exosome suspension and stored at − 80  °C. The total 
RNA was quantified with a NanoDrop ND-1000 spec-
trophotometer (Thermo Fisher Scientific, USA), and the 
quality and size distribution of the samples was examined 
by capillary electrophoresis (Agilent 2100 Bioanalyzer, 
Agilent Technologies, Santa Clara, CA, USA) with a RNA 
6000 Pico chip.
Quantitative real‑time reverse transcription PCR
For miRNA expression analysis, complementary 
DNA was synthesised from 5  μL of total RNA using 
a TaqMan™ MicroRNA Reverse Transcription kit 
(Applied Biosystems, USA). Briefly, 1.33  μL of cDNA 
was combined with TaqMan universal PCR master mix 
II, No UNG, and specific TaqMan microRNA assay 
primers for miR-146a (ID: 000468) and miR-335* (ID: 
002185). The target microRNA data were normalised 
across the samples using a median normalisation proce-
dure [19], and a synthetic Caenorhabditis elegans miR-
39 (cel-miR-39) RNA oligonucleotide was spiked into 
the RNA samples as an internal control (ID: 000200).
All the reactions were run in triplicate, including the 
blank/negative controls without cDNA, on a LightCycler 
480 II real-time PCR system (Roche) under following 
conditions: 95 °C for 10 min, 40 cycles of 95 °C for 15 s 
and 60 °C for 1 min; the data were analysed with Light-
Cycler 480 software (v.1.5). Changes in gene expression 
were calculated using the ΔΔCT method as follows: 
ΔCT = CT (target miRNA) − [(Average_cel-miR-39_Ct 
value of the given sample) − (Median_cel-miR-39_Ct 
value)]; ΔΔCT = ΔCT (exosome miRNA) − ΔCT (MV 
miRNA); the fold change = 2−ΔΔCT. When we com-
pared the influence of UAE, changes were calculated as: 
ΔCT = CT (target miRNA) − [(Average_cel-miR-39_Ct 
value of the given sample) − (Median_cel-miR-39_
Ct value)]; ΔΔCT = ΔCT (MALB exosome or MV 
miRNA) − ΔCT (NO MALB exosome or MV miRNA); 
the fold change = 2−ΔΔCT.
Statistical analysis
Statistical analyses were completed using GraphPad 
Prism software v.6 (GraphPad Software, Inc. La Jolla, 
CA, USA) and SPSS software (SPSS, Chicago, IL, USA). 
To compare EV subgroups, the exosome miRNA data 
were presented as the mean fold change relative to the 
MV group, and to compare the effect of the presence or 
absence of UAE on miRNA levels, relative to the nor-
mal UAE. Mann–Whitney U tests were used to deter-
mine the significant differences in miRNA expression 
in EV subpopulations and the influence of UAE on EV 
miRNA expression. The association between miR-146a 
levels and UAE in exosomes and MVs was analysed by 
Spearman’s correlation coefficient. Receiver operating 
characteristic (ROC) curves were constructed using the 
expression value of each miRNA, and the area under 
the curve (AUC) and 95% confidence interval (CI) was 
calculated for each ROC curve. A p value < 0.05 was 
considered statistically significant.
Results
General characteristics of the study population
Results were obtained from 52 patients with essen-
tial hypertension (mean age = 53.7 ± 7  years, 65% 
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male) in which 24 had increased albuminuria (UAE 
162.78 ± 168.21) and 28 were normalbuminuric (UAE 
3.36/2.28  mg/g). The main characteristics of the study 
population are shown in Table 1.
Isolation and characterisation of urinary extracellular 
vesicles
To validate the EV purification protocol, we analysed the 
morphology of the urinary MVs and exosomes by trans-
mission electron microscopy (Fig.  1a, b). The isolated 
EVs were then subjected to TRPS (Fig. 1c) which clearly 
showed the isolation of two separate EV subpopulations. 
In addition, the exosome fraction exclusively expressed 
TSG-10, and the isolated EVs generally expressed CD9, 
especially in the exosomes. These are well-established 
surface and cytoplasmic markers for exosomes, which 
were also evident in Western blot analysis (Fig.  1d). 
Moreover, non-exosomal markers were highly enriched 
in the positive control cell pellet (HuH7), were only 
slightly present in the MV fraction in the case of calnexin 
and GM-130, and were absent in the exosome-enriched 
fraction.
microRNA‑146a and miR‑335* levels in extracellular vesicle 
fractions
Quantitative RT-PCR indicated that EV miR-146a and 
miR-335* expression in the isolated urinary exosomes 
Table 1 Clinical characteristics of the patient groups
ACEi angiotensin converting enzyme inhibitors, ARB angiotensin II receptor antagonists, CCB calcium channel blocker, HDL high‑density lipoprotein, LDL high‑density 
lipoprotein
The data are expressed as the mean ± SD, unless noted otherwise. The glomerular filtration rates were calculated using the MDRD formula. Comparisons between 
microalbuminuric groups: **p < 0.01, ***p < 0.001
Variables Albuminuric No albuminuric
(n = 24) (n = 28)
Age (years) 52.6 ± 8.4 54.6 ± 5.6
Gender (male) 66.7% 64.3%
Systolic blood pressure (mmHg) 136 ± 11 136 ± 24
Diastolic blood pressure (mmHg) 84 ± 15 88 ± 15
Pulse pressure (mmHg) 52 ± 12 48 ± 16
Glucose (mg/dL) 119 ± 45 118 ± 40
Glycated haemoglobin (%) 6.6 ± 0.3 6.0 ± 0.8
Total cholesterol (mg/dL) 202 ± 34** 174 ± 28
LDL (mg/dL) 131 ± 30** 108 ± 25
HDL (mg/dL) 51 ± 14 49 ± 11
Triglycerides (mg/dL) 148 ± 76 129 ± 59
Plasma creatinine (mg/dL) 0.86 ± 0.06 0.89 ± 0.21
Glomerular filtration rate (mL/min/1.73 m2) 97 ± 27 88 ± 19
Waist (cm) 107 ± 15 99 ± 12
Central obesity (%) 54 50
Body mass index (kg/m2) 32 ± 7 30 ± 6
Obesity (%) 50 39.3
Obesity grade (%)
 Grade I 29 18
 Grade II 8 11
 Grade III 13 11
Diabetes (%) 38 32
Dyslipidemia (%) 88 82
Smoking (%) 46 46
Ex‑smoking (%) 29 14
Urinary albumin excretion/creatinine (mg/g) 162.8 ± 168.2*** 3.3 ± 2.3
Antihypertensive treatment (%)
 ACEi 100 100
 ARB 93 92
 CCB 64 38
 Diuretics 64 63
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was significantly higher than in the MV subpopulation 
(12-fold increase, p < 0.001 in both cases) in hyperten-
sive patients (data not shown). When we compared EV 
fractions in patients with or without increased albumi-
nuria (MALB vs. NO MALB), miR-146a and miR-335 
were present in high amounts in exosomes in both 
groups compared to the MV subpopulation (11-fold 
increase, p < 0.001 (Fig.  2a, b), although this differ-
ence was not significant when compared to the control 
group.
Exosome and microvesicle miR‑146a and miR‑335* levels 
in hypertensive patients with or without albuminuria
Urinary exosome miR-146a was significantly lower 
in the albuminuric group compared to the non-albu-
minuric patients (2.5-fold less, p = 0.017; Fig.  3a). In 
comparison, miR-146a levels were slightly lower in 
the MV-enriched fraction in the albuminuric group, 
although this difference did not reach statistical sig-
nificance (1.4-fold decrease, p = 0.159). Finally, miR-
335* expression levels were similar in the presence or 
absence of albuminuria (Fig.  3b), thus supporting the 
specificity of the results we obtained for miR-146a.
Exosome miR‑146a expression and urinary albumin 
excretion in hypertensive patients
Urinary exosome miR-146a expression was highly cor-
related with urinary excretion of albumin in all the 
hypertensive patients, as shown in Fig.  4 (log-trans-
formed expression levels and UAE: r = −0.65, p < 0.001). 
In contrast, miR-146a was only slightly associated with 
UAE in the MV fraction (r = −0.40, p = 0.011) (Fig. 4). 
There was no correlation between UAE and miR-335* 
in MV or in exosome fractions. The ROC curves con-
structed for miR-146a in the exosome and MV fractions 
Fig. 1 Characterisation of urinary exosomes isolated by ultracentrifugation. Transmission electron microscopy (TEM) micrographs of extracellular 
vesicle isolations stained with uranyl acetate in a exosomes and b microvesicles, bar represents 500 μm. c The size distribution of urinary exosomes 
and microvesicles by tunable resistive pulse sensing analysis of 500 events per sample (n = 4). d Western immunoblotting of exosomes and 
microvesicles isolated from urine using exosomal markers, including Tsg101 and CD9, and non‑exosomal markers including calnexin, nucleoporin, 
p62, GM‑130 and β‑actin. Whole‑cell lysates from HuH7 cells were loaded as a positive control
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to compare their diagnostic value in predicting the 
presence of UAE (Fig.  5) showed an AUC of 0.80 for 
exosome miR-146a (95% CI 0.66, 0.95; p < 0.001) thus 
indicating the predictive power of this miRNA in uri-
nary exosomes in these patients; the AUC for MV miR-
146a was 0.69 (95% CI 0.53–0.85; p = 0.039). These data 
show that expression of miR-146a in exosomes could 
indicate the presence of albuminuria. 
Discussion
This study shows that miR-146a is highly enriched in uri-
nary exosomes compared to the MV subpopulation in 
hypertensive patients. In addition, it is detected at sig-
nificantly lower levels in urinary exosomal samples from 
patients with essential hypertension and albuminuria 
compared to normoalbuminuric hypertensive patients. 
However, there were no differences in the control group. 
EV subtype analysis, a relevant feature of the present 
study, further indicated that urinary exosomal miR-146a 
is a good indicator of incipient renal injury and could be 
used as a potential biomarker for the early detection of 
renal injury. Recognition of the importance of UAE as 
a prognostic marker in hypertension is based on cross-
sectional studies, which demonstrate clustering of cardi-
ovascular risk factors and organ damage associated with 
an increase in UAE [4, 6]. However, the value of a single 
UAE measurement as a risk marker for the develop-
ment of chronic kidney disease or end stage renal disease 
remains controversial. The reason for this discrepancy 
may be the potential mechanisms involved in increasing 
UAE: either via a predominance mechanism through glo-
merular leakage, or because of a reduction in the tubular 
capacity of uptake and metabolization [25].
An association between circulating and tissue miRNA 
expression and renal injury has been described in various 
diseases including diabetic nephropathy, lupus nephritis, 
Fig. 2 Box plots of the miR‑146a and miR‑335* levels in exosomes and microvesicles a in albuminuric (MALB) patients and b in non‑albuminuric 
(NO MALB) hypertensive patients. The relative expression was calculated using the  2−(ΔΔCt) method. The median Ct value of the spike‑in cel‑miR‑39a 
in all the samples was used as a control. The data were compared using the Mann–Whitney U test. EXO exosomes, MV microvesicles
Fig. 3 Box plots of the miR‑146a and miR‑335* levels in exosomes and microvesicles according to the presence of a albuminuria for miR‑146a and 
b for miR‑335*. Relative expression shown was calculated using the  2−(ΔΔCt) method. The median Ct value of the spike‑in cel‑miR‑39a in all samples 
was used as a control. The data were compared using the Mann–Whitney U test. EXO exosomes, MV microvesicles
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IgA nephropathy, and focal segmental glomerulosclero-
sis [26–28]. In addition, recent studies have also shown 
that miRNA profiles are potential indicators of renal 
damage in hypertension. However, most of these stud-
ies analysed plasma and tissue miRNA expression pro-
files [29–31] but, to our knowledge, none have focussed 
exclusively on the potential of urinary exosome miRNAs 
as biomarkers for early renal injury in hypertension. Our 
results indicate that urinary exosomal miR-146a levels 
are significantly lower in albuminuric patients compared 
to normoalbuminuric patients. This observation fits gen-
erally with previous reports showing that low glomerular 
levels of miR-146a had a high ACR at the time of biopsy 
in diabetic patients [23]. In addition, UAE significantly 
negatively correlated with urinary exosomal miR-146a 
expression in our hypertensive patients. These findings 
also suggest that exosomal miR-146a levels could be used 
as a potential indicator of renal injury. Furthermore, our 
ROC curve analysis indicates that urinary exosome miR-
146a levels can discriminate the presence of microalbu-
minuria, although the sensitivity and specificity of this 
discrimination could perhaps be improved in a study 
with a larger cohort.
Fig. 4 Associations between urinary miR‑146a levels with urinary albumin excretion, normalised by urinary creatinine, in hypertensive patients. 
The data were assessed using the Spearman correlation coefficient. Inverse associations were found for exosomal (a) and microvesicle (b) miR‑146a 
expression levels
Fig. 5 ROC analysis of urinary microRNA expression in extracellular vesicles from normalbuminuric and microalbuminuric hypertensive patients. 
Receiver operator characteristic (ROC) curves were constructed using the microRNA expression values for miR‑146a in exosomes (a) and 
microvesicles (b). The area under the curve (AUC) and 95% CI were computed and are shown for each ROC curve. The Wilcoxon and Mann–Whitney 
U tests were used to test the null hypothesis that the AUC is equal to 0.5, and the probability values for each test are shown
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Of note, the miRNA types contained in MVs and 
exosomes were significantly different: in this case miR-
146a and miR-335* were significantly higher in exosomes 
compared to MVs. This suggests that miRNAs are selec-
tively sorted into exosomes rather than MVs, as also 
shown in previous reports [32, 33]. Moreover, miR-146a 
levels also differed according to the presence of UAE, 
indicating that this sorting may depend on the physi-
ological context [34]. These data suggest that miR-146a 
loading into exosomes in hypertensive patients is not 
a passive process and that this sorting may be based on 
biological function.
Previous evidence seems to suggest that miRNA-146a 
is loaded into exosomes as a biological response to the 
different renal pathological processes that occur dur-
ing hypertension (endothelial inflammation, fibrosis, 
podocyte damage, etc.) [9, 20, 21]. Furthermore, it was 
also recently reported that miR-146a was augmented in 
lupus nephritis [19, 22] and that is highly expressed in 
podocytes [23, 24]. Therefore, urinary exosomal miR-
146a levels could be quantified as a potential indicator 
of early-stage renal injury in these patients. Low levels of 
exosomal miR-146a in hypertensive patients with albu-
minuria are likely to promote this pathology and contrib-
utes to advancing renal injury. However, further studies 
looking at a much wider range of miRNAs in different 
EV subpopulations would be required to further support 
the finding that these miRNAs are enriched in exosomes 
relative to MVs in hypertensive patients.
Conclusion
This is the first study to report high levels of miRNA 
enrichment in urinary exosomes compared to MVs in 
hypertensive patients and that urinary exosome levels of 
miR-146a are significantly associated with UAE  and are 
decreased in patients with albuminuria. These findings 
lead us to conclude that urinary exosome miR-146a may 
serve as non-invasive biomarker for early renal injury 
in hypertension, such as albuminuria. As early diagno-
sis remains the key to improving renal damage, further 
studies are warranted to firmly establish urinary exo-
some miRNA signatures indicative of renal damage in 
hypertension.
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